Agriculture Reference
In-Depth Information
Sieradzan, K.A., Fox, S.H., Hill, M., Dick, J.P.R., Crossman, A.R. and Brotchie, J.M. (2001) Cannabinoids
reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study.
Neurology
57, 2108-2111.
Smith, P.F. (2004) Medicinal cannabis extracts for the treatment of multiple sclerosis.
Current Opinion in
Investigational Drugs
5(7), 727-730.
Teixeira-Clerc, F., Julien, B., Grenard, P., Tran van Nhieu, J., Deveaux, V., Hezode, C.,
et al
. (2008) Le
système endocannabinoïde, une nouvelle cible pour le traitement de la fibrose hépatique [The endocan-
nabinoids system as a novel target for the treatment of liver fibrosis].
Pathologie Biologie
56(1), 36-38.
Tramer, M.R., Carroll, D., Campbell, F.A., Reynolds, D.J., Moore, R.A. and McQuay, H.J. (2001)
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.
British Medical Journal
323(7303), 16-21.
Vaney, C., Heinzel-Gutenbrunner, M., Jobin, P., Tschopp, F., Gattlen, B., Hagen, U.,
et al
. (2004) Efficacy, safety and
tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple
sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
Multiple Sclerosis
10(4), 417-424.
Wang, T., Collet, J.P., Shapiro, S. and Ware, M.A. (2008) Adverse effects of medical cannabinoids: a system-
atic review.
CMAJ
178(13), 1669-1678.
Watson, S.J., Benson, J.A. Jr and Joy, J.E. (2000) Marijuana and medicine: assessing the science base.
A summary of the 1999 Institute of Medicine Report.
Archives of General Psychiatry
57, 547-552.
Widmer, M., Hanemann, C.O. and Zajicek, J. (2008) High concentrations of cannabinoids activate apoptosis
in human U373MG glioma cells.
Journal of Neuroscience Research
86(14), 3212-3220.
Yazulla, S. (2008) Endocannabinoids in the retina: from marijuana to neuroprotection.
Progress in Retinal
and Eye Research
27(5), 501-526.
Zajicek, J. (2004) The cannabinoids in Multiple Sclerosis Study. Final results from 12 months follow-up.
Multiple Sclerosis
10(Suppl. 2), 115.
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A.,
et al
. (2003) Cannabinoids for treatment
of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised
placebo-controlled trial.
The Lancet
362(9395), 1517-1526.
Chapter 16
Callaway, J.C. (2004) Hempseed as a nutritional resource: an overview.
Euphytica
140, 65-72.
Leson, G., Pless, P., Grotenhermen, F., Kalant, H. and ElSohly, M.A. (2001) Evaluating the impact
of hemp food consumption on workplace drug tests.
Journal of Analytical Toxicology
25, 691-698.
Matthäus, B. (1997) Antinutritive compounds in different oilseeds.
Fett/Lipid
99, 170-174.
Chapter 17
Arnaud, L. (1999) Qualification physique des matériaux de construction à base de chanvre. Progress report
June 1998 to June 1999. ENTPE (Laboratoire de Géomatériaux), France, 73 pp (
www.entpe.fr).
Arnaud, L. (1999) Les bétons de chènevottes: approches mécaniques et thermiques. La journée scientifique
du chanvre, 21 August 1999, AFLAM, Montjean sur Loire, France.
Arnaud, L. (2000) Qualification physique des matériaux de construction à base de chanvre. Progress report
June 1999 to June 2000. ENTPE (Laboratoire de Géomatériaux), France, 73 pp.
Arnaud, L. (2000) Les propriétés des mortiers à base de chanvre. Conférence au CRAB-Info Batir de Lyon,
26 October 2000, France.
